Matt Hoffman, Senior Editor for NeurologyLive, has covered medical news for MJH Life Sciences, NeurologyLive’s parent company, since 2017. He hosts the NeurologyLive Mind Moments podcast, as well as Second Opinion on Medical World News. Follow him on Twitter @byMattHoffman or email him at email@example.com
The synthetic cannabis-like therapy dronabinol was effectively used to treated patients with obstructive sleep apnea, offering a potentially better alternative to CPAP machines.
Phyllis Zee, MD, PhD
The synthetic cannabis-like therapy dronabinol was effectively used to treated patients with obstructive sleep apnea (OSA), offering a potentially more effective option than continuous positive airway pressure (CPAP) devices, according to findings published journal SLEEP.
Conducted by the University of Illinois at Chicago and Northwestern Medicine, the study examined 73 adults with moderate to severe obstructive sleep apnea, revealing that the synthetic version of Delta-9 tetrahydrocannabinol (THC) was associated with a lower overall apnea/hypopnea index (AHI) compared with placebo.
Participants were randomized to either 2.5 mg dronabinol (n = 21), 10 mg dronabinol (n = 27), or placebo (n = 25) once daily an hour before sleep for 6 weeks. At baseline, AHI was measured (25.9 ±11.3) as well as Epworth Sleepiness Scale (ESS) scores (11.45 ±3.8) and the mean latency of maintenance of wakefulness (MWT) test (19.2 ±11.8 minutes)
After the 6-week period, the 10-mg group had the highest overall satisfaction (P = .4), experiencing an AHI reduction of 12.9 ±4.3 events per hour (P = .003). The 2.5-mg group experienced a reduction in AHI of 10.7 ±4.4 events per hour (P = .04) compared with placebo. MWT sleep latencies were unchanged from baseline in all groups.
Dronabinol in the 10-mg dose also reduced ESS score by -3.8 ±0.8 points from baseline (P <.0001) and 2.3 ±1.2 points compared to placebo (P = .05).
"Dronabinol is a medication, whereas the current therapies available involve either mechanical approaches to open the airway, or surgical approaches of the upper airway, including a nerve stimulation device," Phyllis Zee, MD, PhD, the Benjamin and Virginia T. Boshes professor of neurology at Northwestern University Feinberg School of Medicine and director of the Northwestern Medicine Sleep Disorders Center, said. "It clearly will provide more choices for providers, and open up the door for the development of other drug-based therapies that can be tailored to individual patient characteristics and needs."
The biggest issue with CPAP is that they struggle when it comes to treatment adherence. Co-lead author David C. Carley, PhD, the Katherine M. Minnich, endowed professor of narcolepsy, sleep, and health research at the University of Illinois at Chicago’s College of Nursing, said in a statement that on average, patients only use the devices for an estimated 4 hours a night, if at all.
"The best they can get is a roughly 50% improvement in their apnea [with CPAP]. When people take a pill to treat apnea, they are treated for the entire night,” Carley said.
Dronabinol did not face this adherence issue—during the trial, treatment adherence was consistent among all groups (0.3 ±0.6 missed doses/week). Compared to even complete compliance with mechanical treatment with CPAP, the severity of OSA was reduced by 33% with dronabinol.
"The CPAP device targets the physical problem but not the cause," Zee said. "The drug targets the brain and nerves that regulate the upper airway muscles. It alters the neurotransmitters from the brain that communicate with the muscles. [A] better understanding of this will help us develop more effective and personalized treatments for sleep apnea."
Carley said there is a "tremendous" need for more treatment options for OSA. He noted that researchers have attempted to find a treatment for OSA without success for almost 35 years. Zee noted that "pharmacotherapy has the potential to expand treatment options," as these other options become ineffective for more and more patients.
"The next step is to test the effectiveness and safety in larger multicenter studies," Zee said. "Our early results indicate the potential for pharmacotherapy as a treatment for OSA. However, larger scale studies are needed assess the generalizability of these findings to the treatment of OSA."
Dronabinol is currently approved by the US Food and Drug Administration for the treatment of nausea and vomiting for patients undergoing chemotherapy.
Carley DW, Prasad B, Reid KJ, et al. Pharmacotherapy of Apnea by Cannabimimetic Enhancement, the PACE Clinical Trial: Effects of Dronabinol in Obstructive Sleep Apnea. SLEEP. 2018;41(1):184.